Bedrijfsoverzicht
Vanda Pharmaceuticals Inc. is a biopharmaceutical entity dedicated to the research, development, and commercialization of novel therapies designed to address significant unmet medical needs globally. The company operates within the healthcare sector, specifically the biotechnology industry, which focuses on the discovery and production of biological agents rather than small-molecule drugs. With a market capitalization of $426.76M, an annual revenue of $216.10M, and a workforce comprising 533 employees, Vanda maintains a mid-cap profile typical for specialized biotechnology firms. These valuation and revenue figures indicate that the company has established a commercial footprint sufficient to support ongoing R&D activities while managing a substantial operational team, positioning it as a niche player in the broader pharmaceutical landscape.
Financiële gezondheid
Vanda Pharmaceuticals reported a revenue of $216.10M over the trailing twelve months, yet generated a net income of -$220.47M and an EBITDA of -$143.06M. The substantial gap between the positive revenue of $216.10M and the negative net income of -$220.47M reveals a cost structure where expenses, including research, development, and general administrative costs, significantly exceed gross profits. The company recorded a free cash flow of -$49.36M, indicating a consumption of cash reserves to fund operations and capital expenditures, which limits immediate financial flexibility but is common in the biotech sector. The gross margin stands at 94.0%, demonstrating high pricing power or low cost of goods sold relative to sales, while the operating margin of -70.5% and profit margin of -102.0% highlight the intense expense burden inherent in scaling biopharmaceutical ventures. The company holds $263.85M in cash against $12.62M in debt, resulting in a debt-to-equity ratio of 3.86, which suggests a leveraged balance sheet reliant on equity financing rather than creditor support. Despite the high debt-to-equity ratio, a current ratio of 2.39 indicates robust short-term liquidity, as current assets are more than twice the value of current liabilities. Return on equity is -50.9% and return on assets is -16.5%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a typical characteristic for companies in the growth phase of the biotechnology lifecycle.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to negative earnings, whereas the forward P/E is 36.10, implying that the market expects future earnings to become positive and grow significantly to justify current pricing. The price-to-book ratio of 1.30 suggests the market values the company at 1.3 times its book value, indicating a moderate premium that accounts for the company's intangible assets and potential future pipeline value. Alternative valuation metrics such as a price-to-sales ratio of 1.97 and an EV/EBITDA of -1.23 provide context for investors, showing that valuation is primarily driven by revenue multiples rather than profitability or cash flow generation. The stock has traded between a 52-week low of $3.81 and a 52-week high of $9.94, meaning the current share price sits at the upper end of its recent trading range relative to the established volatility band. The beta of 0.71 indicates that the stock exhibits lower price volatility than the broader market, moving approximately 29% less than the market average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is 7.6%, while earnings growth is N/A due to the company's continued losses. Since earnings are not growing in a positive trajectory, the relationship between revenue expansion and profitability remains negative, implying that top-line growth has not yet translated to bottom-line success. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all available capital back into research and development rather than distributing income to shareholders. This growth-oriented strategy prioritizes the expansion of the commercial portfolio, such as the acute treatment of manic or mixed episodes associated with bipolar I disorder, over immediate income generation for investors.